Congressional Inquiry into Alzheimer’s Drug Faults Its Maker and F.D.A.
The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
 |
| The investigation found that Biogen, Aduhelm’s manufacturer, initially priced the drug at $56,000 a year because it wanted a “blockbuster” that would “establish Aduhelm as one of the top pharmaceutical launches of all time,” according to documents.Pool photo by Jessica Rinaldi |
